ABHD17B
MOLECULAR TARGETabhydrolase domain containing 17B
ABHD17B (abhydrolase domain containing 17B) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ABHD17B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Clotrimazole | 1.39 | 3 |
| 2 | Hexachlorophene | 1.39 | 3 |
| 3 | Anthralin | 1.10 | 2 |
| 4 | Aurintricarboxylic Acid | 1.10 | 2 |
| 5 | Tetracycline | 1.10 | 2 |
| 6 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 0.69 | 1 |
| 7 | Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). | 0.69 | 1 |
| 8 | Domperidone | 0.69 | 1 |
| 9 | Oxytetracycline | 0.69 | 1 |
| 10 | rafoxanide | 0.69 | 1 |
About ABHD17B as a Drug Target
ABHD17B (abhydrolase domain containing 17B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented ABHD17B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ABHD17B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.